Agios Pharmaceuticals, Inc. (AGIO) Reaches $70.29 After 7.00% Down Move; 3 Bullish Analysts Covering Cobham plc (LON:COB)

January 16, 2018 - By reb123z

Among 20 analysts covering Cobham PLC (LON:COB), 3 have Buy rating, 3 Sell and 14 Hold. Therefore 15% are positive. Cobham PLC had 180 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Liberum Capital on Thursday, August 4 with “Buy”. Deutsche Bank maintained Cobham plc (LON:COB) rating on Thursday, February 11. Deutsche Bank has “Sell” rating and GBX 260 target. The stock has “Buy” rating by Liberum Capital on Wednesday, January 11. The rating was maintained by Goldman Sachs on Thursday, January 12 with “Neutral”. The stock of Cobham plc (LON:COB) has “Hold” rating given on Friday, May 20 by Canaccord Genuity. The rating was maintained by JP Morgan on Monday, July 18 with “Neutral”. As per Tuesday, April 26, the company rating was maintained by Liberum Capital. The rating was maintained by RBC Capital Markets with “Sector Perform” on Friday, October 2. Barclays Capital maintained the shares of COB in report on Friday, August 5 with “Overweight” rating. The stock has “Hold” rating by Liberum Capital on Tuesday, September 26. See Cobham plc (LON:COB) latest ratings:

12/01/2018 Broker: Liberum Capital Rating: Hold Old Target: GBX 140.00 New Target: GBX 130.00 Maintain
05/01/2018 Broker: JP Morgan Rating: Neutral Old Target: GBX 135.00 New Target: GBX 132.00 Maintain
20/12/2017 Broker: Barclays Capital Rating: Equal Weight Old Target: GBX 135.00 New Target: GBX 135.00 Maintain
11/12/2017 Broker: Goldman Sachs Rating: Sell Maintain
16/11/2017 Broker: JP Morgan Rating: Neutral Old Target: GBX 145.00 New Target: GBX 145.00 Maintain
15/11/2017 Broker: Liberum Capital Rating: Hold Old Target: GBX 140.00 New Target: GBX 140.00 Maintain
26/09/2017 Broker: Liberum Capital Rating: Hold Old Target: GBX 140.00 New Target: GBX 140.00 Maintain
31/08/2017 Broker: Deutsche Bank Rating: Hold Old Target: GBX 115.00 New Target: GBX 120.00 Maintain
07/08/2017 Broker: Liberum Capital Rating: Hold Old Target: GBX 115.00 New Target: GBX 140.00 Maintain
07/08/2017 Broker: Barclays Capital Rating: Equal Weight Old Target: GBX 135.00 New Target: GBX 135.00 Maintain

The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a huge mover today! The stock decreased 6.42% or $4.82 during the last trading session, reaching $70.29. About 749,323 shares traded or 87.32% up from the average. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since January 16, 2017 and is uptrending. It has underperformed by 8.18% the S&P500.The move comes after 8 months negative chart setup for the $3.43B company. It was reported on Jan, 16 by Barchart.com. We have $65.37 PT which if reached, will make NASDAQ:AGIO worth $239.89M less.

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 41 analyst reports since July 23, 2015 according to SRatingsIntel. SunTrust initiated it with “Buy” rating and $57 target in Wednesday, March 30 report. J.P. Morgan maintained the shares of AGIO in report on Monday, September 18 with “Buy” rating. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Outperform”. The firm earned “Buy” rating on Monday, June 13 by Canaccord Genuity. The stock has “Overweight” rating by JP Morgan on Monday, June 13. The firm has “Outperform” rating given on Thursday, November 2 by Credit Suisse. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Buy” rating given on Tuesday, August 1 by Cowen & Co. Canaccord Genuity maintained the shares of AGIO in report on Monday, June 5 with “Buy” rating. The firm earned “Buy” rating on Tuesday, October 3 by SunTrust. The rating was downgraded by Leerink Swann on Monday, December 7 to “Market Perform”.

Analysts await Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report earnings on February, 15. They expect $-1.65 EPS, down 23.13% or $0.31 from last year’s $-1.34 per share. After $-1.59 actual EPS reported by Agios Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.77% negative EPS growth.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $3.43 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Since August 1, 2017, it had 0 insider purchases, and 15 insider sales for $15.08 million activity. Another trade for 35,000 shares valued at $2.35 million was sold by Schenkein David P. Biller Scott also sold $195,000 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares. $390,000 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares were sold by Bowden Christopher. Cantley Lewis Clayton Jr. had sold 4,000 shares worth $227,400.

Investors sentiment decreased to 1.21 in Q3 2017. Its down 0.83, from 2.04 in 2017Q2. It dropped, as 22 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 29 funds opened positions while 51 raised stakes. 44.69 million shares or 0.07% less from 44.72 million shares in 2017Q2 were reported. Jpmorgan Chase has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Credit Suisse Ag stated it has 0.01% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Loomis Sayles Limited Partnership has 0.03% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Capital Int Limited Ca accumulated 1.06% or 241,337 shares. Goldman Sachs Group Inc Incorporated holds 0.02% or 932,156 shares in its portfolio. Moreover, Clearbridge Ltd Limited Liability Company has 0.1% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 1.53M shares. Weiss Multi, Alabama-based fund reported 10,000 shares. Fincl Bank Of Ny Mellon Corporation holds 0% or 176,405 shares in its portfolio. State Bank Of Montreal Can accumulated 0% or 2,031 shares. 35,800 were accumulated by Platinum Mngmt. Moreover, Parallax Volatility Advisers Limited Partnership has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 30,734 shares. Oppenheimer & Co Inc holds 21,445 shares. Bluecrest Cap Management Ltd, Guernsey-based fund reported 7,498 shares. Alkeon Cap Mngmt reported 0.23% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Marshall Wace Ltd Liability Partnership accumulated 9,587 shares.

Cobham plc provides a range of technologies and services to commercial, defense, and security markets in the United Kingdom, the United States, Other European countries, Australia, andinternationally. The company has market cap of 3.13 billion GBP. The firm operates in four divisions: Communications and Connectivity, Mission Systems, Advanced Electronic Solutions, and Aviation Services. It currently has negative earnings. The Communications and Connectivity segment offers equipment and solutions for the aerospace, avionics, satellite and radio, wireless, and mobile connectivity markets.

The stock increased 0.23% or GBX 0.3 during the last trading session, reaching GBX 131.4. About 5.52 million shares traded. Cobham plc (LON:COB) has 0.00% since January 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: